Drug
Intervention1 Fxs5626
Intervention1 Fxs5626: highest development phase Phase 2/3, developed by Shanghai Fosun Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Shanghai Fosun Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| Intervention1: FXS5626 Tablets NCT07840820 | Phase 2/3 | Non-segmental Vitiligo |
Latest
No recent events.
Follow Intervention1 Fxs5626 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.